1. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306) 
D.P. Modest, I. Ricard, S. Stintzing, L. Fischer von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, S.-E. Al-Batran, T. Heintges, C. Kahl, G. Seipelt, F. Kullmann, W. Scheithauer, M. Moehler, C.B. Westphalen, J.W. Holch, J.C. von Einem, S. Held, V. Heinemann 
European Journal of Cancer 
Volume 84, Pages (October 2017)
DOI: /j.ejca
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Fig. 1
Comparison of fitted Cox model curves (Cox) with Kaplan–Meier curves (KM) of overall survival in the KRAS exon 2 wild-type intention-to-treat (ITT) and in the RAS wild-type population (A, B), in the KRAS exon 2 wild-type ITT in the RAS wild-type population when a change-point is included (C, D). The censoring times are not marked to not overload the graphs. ‘Cetuximab’ and ‘bevacizumab’ indicate study arms.
European Journal of Cancer  , DOI: ( /j.ejca )
Copyright © 2017 Elsevier Ltd Terms and Conditions

3. Fig. 2
Time interval assessment of patients receiving any or no active therapy (A, B). Patients with treatment, including discrimination by line of therapy; patients with more than one line of therapy within a time interval were added into each line's population (C, D). Full populations were 297 (FOLFIRI + cetuximab = arm A) and 295 patients (FOLFIRI + bevacizumab = arm B) in KRAS exon 2 wild-type population, 199 (arm A) and 201 patients (arm B) in RAS wild-type population, respectively. All analyses based on non-missing data. Proportion of patients under the first, second and third line or any of these three treatments for the KRAS exon 2 wild-type intention-to-treat population (E) and in the RAS wild-type population (F). The probabilities of being under treatment were constructed relative to the number of patients alive at this time. We supposed that the missing treatment-start and -stop dates were missing completely at random so that patients with any missing treatment dates were excluded from the analyses/plot.
European Journal of Cancer  , DOI: ( /j.ejca )
Copyright © 2017 Elsevier Ltd Terms and Conditions

4. Fig. 3
Duration of systemic treatment within time intervals in study arms (A, B). Operations in the study arms in time intervals (C, D). Full populations were 297 (FOLFIRI + cetuximab = arm A) and 295 patients (FOLFIRI + bevacizumab = arm B) in KRAS exon 2 wild-type population, 199 (arm A) and 201 patients (arm B) in RAS wild-type population, respectively. All analyses based on non-missing data.
European Journal of Cancer  , DOI: ( /j.ejca )
Copyright © 2017 Elsevier Ltd Terms and Conditions